Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study

Next Previous
Trial Profile

Defibrotide for Patients With Hepatic Veno-occlusive Disease: A Treatment IND Study

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Defibrotide (Primary)
  • Indications Hepatic veno-occlusive disease
  • Focus Expanded access; Registrational; Therapeutic Use
  • Acronyms T-IND
  • Sponsors Jazz Pharmaceuticals Inc

Most Recent Events

  • 04 Dec 2018 Results of a Pooled Analysis of CUP and T-IND trials (n=534) assessing the survival By Defibrotide Timing of Initiation in Adults with Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome Following HSCT, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
  • 17 Jun 2018 Results (n=1000) presented at the 23rd Congress of the European Haematology Association
  • 12 Dec 2017 Final results of adult subgroup outcomes data (n=1000) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top